The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The latest report accuses the PBMs — CVS Caremark ... the expense of the American health care system, according to the FTC. Specifically, the companies were able to generate more than $7.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback